Talis Biomedical
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Talis Biomedical generated cash of -$53,240,000, which is more than the previous year. Cash used in financing activities reached the amount of $33,000 last year. Net change in cash is therefore -$53,693,000.
Cash Flow
| 2018 | -20.94M | -533K | 8K |
|---|---|---|---|
| 2019 | -24.32M | -578K | 39.61M |
| 2020 | -87.02M | -8.20M | 246.75M |
| 2021 | -171.38M | -2.86M | 234.42M |
| 2022 | -100.13M | -1.61M | 406K |
| 2023 | -53.24M | -486K | 33K |
TLIS Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 131.96M | 233.31M | 173.13M | 21.60M | 6.89M | 28.36M |
Operating activities | ||||||
Net income | -62.00M | -113.01M | -192.03M | -91.13M | -27.47M | -21.33M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 770K | 8.83M | 1.57M | 763K | 726K | 647K |
Stock-based compensation expense | 4.35M | 5.36M | 9.20M | 3.68M | 965K | 0 |
| Deferred income tax benefit | 4.35M | 5.36M | 9.20M | 3.68M | 965K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 259K | -125K | 288K | -238K | 192K | 0 |
Inventories | 0 | 0 | -288K | -4.00M | -192K | 0 |
Accounts payable | -2.42M | -1.19M | 216K | 3.2M | 185K | 599K |
Cash generated by operating activities | -53.24M | -100.13M | -171.38M | -87.02M | -24.32M | -20.94M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -486K | -1.61M | -2.86M | -8.20M | -578K | -533K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -486K | -1.61M | -2.86M | -8.20M | -578K | -533K |
Financing activities | ||||||
Common Stock Issued | 33K | 406K | 232.54M | 248.18M | 39.61M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 15M | 0 |
Cash used in financing activities | 33K | 406K | 234.42M | 246.75M | 39.61M | 8K |
Net Change In Cash | -53.69M | -101.34M | 60.17M | 151.52M | 14.70M | -21.46M |
Cash at end of period | 78.27M | 131.96M | 233.31M | 173.13M | 21.60M | 6.89M |
| Data source | Data source | Data source | Data source |